Answers are grounded in this paper and cite their sources.
The use of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance. (Funded by Santaris Pharma; ClinicalTrials.gov number, NCT01200420.).
No takes yet. Share an insight, caveat, or question.
Janssen et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: